Drugs / NY-ESO-1 157-165 (165V)
last change Jan 2023 re-read 3 minutes ago

NY-ESO-1 157-165 (165V)

Developed for
cutaneous melanoma
Investigated by
Bristol-Myers Squibb · H. Lee Moffitt Cancer Center and Research Institute · Medarex · National Cancer Institute (NCI)

Trials 1

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01176474 Aug 2010 → Aug 2020 cutaneous melanoma H. Lee Moffitt Cancer Center and Research Institute Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as NY-ESO-1 157-165 (165V) ClinicalTrials.gov intervention name — accepted as the source's own label NCT01176474 ↗